1. Home
  2. KALV vs INN Comparison

KALV vs INN Comparison

Compare KALV & INN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$16.32

Market Cap

551.2M

Sector

Health Care

ML Signal

HOLD

Logo Summit Hotel Properties Inc.

INN

Summit Hotel Properties Inc.

HOLD

Current Price

$4.84

Market Cap

568.0M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
INN
Founded
N/A
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
551.2M
568.0M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
KALV
INN
Price
$16.32
$4.84
Analyst Decision
Strong Buy
Sell
Analyst Count
8
2
Target Price
$26.43
$4.50
AVG Volume (30 Days)
1.8M
685.5K
Earning Date
11-10-2025
11-04-2025
Dividend Yield
N/A
6.72%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,426,000.00
$727,443,000.00
Revenue This Year
N/A
$0.91
Revenue Next Year
$204.16
$2.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.30
$3.57
52 Week High
$17.28
$6.99

Technical Indicators

Market Signals
Indicator
KALV
INN
Relative Strength Index (RSI) 67.20 37.48
Support Level $13.28 $5.11
Resistance Level $16.80 $5.29
Average True Range (ATR) 1.09 0.18
MACD 0.28 -0.04
Stochastic Oscillator 79.32 14.47

Price Performance

Historical Comparison
KALV
INN

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About INN Summit Hotel Properties Inc.

Summit Hotel Properties Inc is a U.S.-based hotel investment company focusing on select-service hotels in the upscale and upper-midscale properties in the U.S. Substantially all of Summit's assets are held and operated by its Operating Partnership, Summit Hotel OP, LP, in which the company holds general and limited partnership interests. The firm has one segment in activities related to investing in real estate. Summit's revenue streams include Room and Other hotel operations revenue. Room comprises the majority of total revenues. The firm's hotels are located in various markets, such as corporate offices, retail centers, airports, state capitols, convention centers, and leisure attractions. Summit's hotels operate under brands, including Marriott, Hilton, Hyatt, and Holiday Inn.

Share on Social Networks: